Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 4:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 548 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Cholesterol Clear all
Completed Phase 3 Interventional

The VA HDL Intervention Trial (HIT): Secondary Prevention of Coronary Heart Disease in Men With Low HDL-Cholesterol and Desirable LDL-Cholesterol

NCT00283335
View directory record Official record
Conditions
Coronary Heart Disease
Interventions
gemfibrozil, Placebo
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Up to 73 Years · Male only
Enrollment
2,531 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 1999
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 20, 2015 · Synced Jul 21, 2026, 4:44 PM EDT
Completed Not applicable Interventional

Safety, Effectiveness, and Tolerability of Ezetimibe Combined With Statins for the Treatment of High Cholesterol in HIV Infected Adults

NCT00099684
View directory record Official record
Conditions
HIV Infections
Interventions
Ezetimibe
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
41
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2012 · Synced Jul 21, 2026, 4:44 PM EDT
Terminated Phase 2Phase 3 Interventional

Open Label Safety & Pharmacodynamic Study 24Wk w/DIO-902 Combo w/Metformin & Atorvastatin in T2DM Patients

NCT00622089
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
DIO-902
Drug
Lead sponsor
DiObex
Industry
Eligibility
18 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
12
States / cities
Muscle Shoals, Alabama • Tucson, Arizona • Jonesboro, Arkansas + 9 more
Source: ClinicalTrials.gov public record
Updated May 27, 2008 · Synced Jul 21, 2026, 4:44 PM EDT
Completed Phase 3 Interventional Results available

Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults

NCT02344290
View directory record Official record
Conditions
HIV, Cardiovascular Diseases
Interventions
Pitavastatin, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
40 Years to 75 Years
Enrollment
7,769 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
91
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 59 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Jul 21, 2026, 4:44 PM EDT
Completed Phase 1Phase 2 Interventional

Statins and Lupus: Effects of Statins on Clinical Lupus Parameters, Serological Markers and Toll-like Receptors

NCT00519363
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
atorvastatin
Drug
Lead sponsor
The Center for Rheumatic Disease, Allergy, & Immunology
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 23, 2010 · Synced Jul 21, 2026, 4:44 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Healthy Fatty Acids in Transition

NCT00937963
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Palm DAG Oil
Dietary Supplement
Lead sponsor
Penn State University
Other
Eligibility
30 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 20, 2023 · Synced Jul 21, 2026, 4:44 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony)

NCT02666664
View directory record Official record
Conditions
Hypercholesterolemia, Atherosclerotic Cardiovascular Diseases
Interventions
ETC-1002, Placebo
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2,230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
48
States / cities
Huntsville, Alabama • Cottonwood, Arizona • Phoenix, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated May 10, 2020 · Synced Jul 21, 2026, 4:44 PM EDT
Completed Phase 2 Interventional Results available

Study of Atorvastatin/Fenofibrate (LCP-AtorFen) Combination Therapy in Dyslipidemia

NCT00504829
View directory record Official record
Conditions
Dyslipidemia
Interventions
LCP-AtorFen, atorvastatin, fenofibrate
Drug
Lead sponsor
Veloxis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 16, 2020 · Synced Jul 21, 2026, 4:44 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Impact of Ketogenic Diets on Cardiovascular Health in Adults With Epilepsy

NCT02694094
View directory record Official record
Conditions
Hypercholesterolemia, Carotid Intimal Medial Thickness 1, Seizure, Epilepsy, Cardiovascular Disease, Cerebrovascular Disease, Heart Disease, Coronary Disease
Interventions
Modified Atkins or Ketogenic Diet
Dietary Supplement
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced Jul 21, 2026, 4:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparison of KADIAN 100 mg When Dosed With Alcohol Under Fasting and Fed Conditions Compared to Water

NCT00768183
View directory record Official record
Conditions
Healthy
Interventions
KADIAN Capsule + alcohol (under fasting conditions), KADIAN Capsule + water (under fasting conditions), morphine sulfate IR oral solution + water, KADIAN Capsule + alcohol (under fed conditions)
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
21 Years to 40 Years · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 15, 2020 · Synced Jul 21, 2026, 4:44 PM EDT
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Effect of Rosuvastatin on Endothelial Function

NCT00986999
View directory record Official record
Conditions
HIV Infections, Cardiovascular Disease
Interventions
rosuvastatin
Drug
Lead sponsor
University of Hawaii
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Jan 28, 2015 · Synced Jul 21, 2026, 4:44 PM EDT
Active, not recruiting Phase 3 Interventional

A Randomized Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Cardiovascular Disease

NCT03705234
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease
Interventions
Inclisiran, Placebo
Drug
Lead sponsor
University of Oxford
Other
Eligibility
40 Years and older
Enrollment
16,124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2049
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Jul 21, 2026, 4:44 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of Dietary Milk Polar Lipids on Serum Cholesterol and Gut Microbiota in Healthy Adults

NCT04208815
View directory record Official record
Conditions
Serum Cholesterol, Gut Microbiome
Interventions
Milk Polar Lipids, Milk Fat
Other
Lead sponsor
University of Connecticut
Other
Eligibility
18 Years to 50 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Storrs, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 12, 2022 · Synced Jul 21, 2026, 4:44 PM EDT
Completed Phase 2 Interventional Results available

Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of SBC-102 (Sebelipase Alfa) in Adult Subjects With Lysosomal Acid Lipase Deficiency

NCT01488097
View directory record Official record
Conditions
Cholesterol Ester Storage Disease (CESD), Lysosomal Acid Lipase Deficiency, LAL-Deficiency
Interventions
sebelipase alfa
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
5
States / cities
Eureka, California • Sacramento, California • San Francisco, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2018 · Synced Jul 21, 2026, 4:44 PM EDT
Completed Phase 3 Interventional Results available

Aggressive Cholesterol Therapy to Inhibit Vein Graft Events After CABG (ACTIVE Trial)

NCT01528709
View directory record Official record
Conditions
Saphenous Vein Graft Disease
Interventions
Atorvastatin 80 mg daily, Atorvastatin 10 mg daily
Drug
Lead sponsor
Boca Raton Regional Hospital
Other
Eligibility
18 Years and older
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Sep 6, 2018 · Synced Jul 21, 2026, 4:44 PM EDT
Terminated Phase 4 Interventional Results available

CT COMPARE: CT Coronary Angiography to Measure Plaque Reduction

NCT02740699
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Rosuvastatin, Atorvastatin, Cardiac Computed Tomography (CT), Cardiac Magnetic Resonance Image (MRI)
Drug · Radiation
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
40 Years to 75 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Jul 21, 2026, 4:44 PM EDT
Completed Phase 2 Interventional Results available

Short-term Behavioral Effects of Cholesterol Therapy in Smith-Lemli-Opitz Syndrome

NCT00114634
View directory record Official record
Conditions
Smith-Lemli-Opitz Syndrome
Interventions
Egg yolk preparation with cholesterol, Egg substitute, without cholesterol
Dietary Supplement
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
4 Years to 17 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 28, 2016 · Synced Jul 21, 2026, 4:44 PM EDT
Withdrawn Phase 1 Interventional

A Pilot Study on the Effect of Vitamin D Treatment in Patients With Statin-Associated Myalgia

NCT01274104
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Vitamin D3, Placebo
Dietary Supplement · Other
Lead sponsor
Avera McKennan Hospital & University Health Center
Other
Eligibility
18 Years to 88 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Apr 21, 2015 · Synced Jul 21, 2026, 4:44 PM EDT
Completed Phase 3 Interventional Results available

A Randomized Study to Evaluate the Effect of an "Inclisiran First" Implementation Strategy Compared to Usual Care in Patients With Atherosclerotic Cardiovascular Disease and Elevated LDL-C Despite Receiving Maximally Tolerated Statin Therapy (VICTORION-INITIATE)

NCT04929249
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease
Interventions
Inclisiran
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
43
States / cities
Little Rock, Arkansas • Los Angeles, California • Greenwich, Connecticut + 32 more
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Jul 21, 2026, 4:44 PM EDT
Completed Phase 2 Interventional Results available

A Research Study Looking at How NNC0385-0434 Tablets Work to Lower Blood Cholesterol in People With Heart Disease or a High Risk of Heart Disease

NCT04992065
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease
Interventions
NNC0385-0434 A 15 mg, NNC0385-0434 A 40 mg, Placebo I A (for NNC0385-0434 A 15 mg), NNC0385-0434 A 100 mg, Placebo I A (for NNC0385-0434 A 40 mg), Placebo II A (for NNC0385-0434 A 100 mg), Evolocumab 140 mg/mL, Repatha®
Drug · Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
40 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
13
States / cities
Palm Springs, California • Boca Raton, Florida • Fort Lauderdale, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2025 · Synced Jul 21, 2026, 4:44 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Effects of a Supplement Derived From Palm Oil on Cholesterol Levels in the Blood

NCT02634606
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Gamma Delta Tocotrienols - Low Dose, Gamma Delta Tocotrienols - High Dose, Sugar Pill
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
35 Years to 70 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 11, 2019 · Synced Jul 21, 2026, 4:44 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Metabolic Response to Chardonnay Grape Marc Powder

NCT03203915
View directory record Official record
Conditions
Dyslipidemia, Obesity
Interventions
Chardonnay grape marc marc high polyphenol dose (120mg), Chardonnay grape marc powder low polyphenol dose (75mg), Placebo (0mg)
Dietary Supplement
Lead sponsor
USDA, Western Human Nutrition Research Center
Federal
Eligibility
35 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Jul 21, 2026, 4:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY2484595 on Pharmacokinetics in Healthy Participants

NCT01448824
View directory record Official record
Conditions
Healthy Participants
Interventions
LY2484595, Placebo, Ketoconazole
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
Daytona Beach, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 1, 2019 · Synced Jul 21, 2026, 4:44 PM EDT
Active, not recruiting Phase 4 Interventional

VictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart Disease

NCT06249165
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease
Interventions
Inclisiran
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
23
States / cities
Birmingham, Alabama • Orange, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Jul 21, 2026, 4:44 PM EDT